Voluntary nationwide recall: Sodium Bicarb and Atropine (Hospira – December)
Jan. 2024Pharmacy Updates
Hospira Inc. is recalling several lots of 4.2% Sodium Bicarbonate Injection, USP, 8.4% Sodium Bicarbonate Injection, USP, and Atropine Sulfate Injection, USP. Sodium Bicarbonate is used for the treatment of metabolic acidosis (a buildup of acid in the body). Atropine Sulfate is used for temporary blockade of severe or life-threatening muscarinic effects (effects on certain nerves of the body).
These drugs are being recalled because particles of glass were found in the drug(s) during a routine inspection of samples. Administration of an injectable product that contains particulate matter may result in local irritation or swelling, blockage of blood vessels, or life-threatening blood clot events.
As of the date of Hospira’s recall announcement, Dec. 21, 2023, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below. If you have an affected lot of Sodium Bicarbonate Injection or Atropine Sulfate Injection, you should stop using the item and return it to the place of purchase or discard it. To learn more about this recall, you can take one or more of the steps below.
These drugs are being recalled because particles of glass were found in the drug(s) during a routine inspection of samples. Administration of an injectable product that contains particulate matter may result in local irritation or swelling, blockage of blood vessels, or life-threatening blood clot events.
As of the date of Hospira’s recall announcement, Dec. 21, 2023, there have been no reports of adverse events related to this recall. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below. If you have an affected lot of Sodium Bicarbonate Injection or Atropine Sulfate Injection, you should stop using the item and return it to the place of purchase or discard it. To learn more about this recall, you can take one or more of the steps below.
- Talk to your doctor or pharmacist.
- Call Sedgwick Inc. at 1-800-805-3093. TTY users should call 711. Help is available Monday through Friday from 8 a.m. to 5 p.m. EST.
- Visit the FDA website.
Recent Announcements
The importance of PRD forms for complex patients and staying updated on changes
Personal representative designation (PRD) forms are critical to the care process for patients and providers alike. Not only do PRDs support accurate, efficient, and compliant patient care—they also streamline administrative processes.Aug. 2025Important Notices
Important announcement: UPMC Health Plan retires MP.PA.147
This communication is in regards to UPMC Health Plan Policy MP.PA.147 – Diagnostic and Surveillance Colonoscopy, 18 Years Old and Older. UPMC Health Plan previously communicated that the prior authorization requirement under this policy would be paused until Sept. 1, 2025. However, policy MP.PA.147 has been retired, and this policy will no longer be implemented or active.Aug. 2025Important Notices
CMS expands Medicare Advantage RADV audits to all eligible plans
On May 21, 2025, the Centers for Medicare & Medicaid Services (CMS) announced a substantial expansion of its Risk Adjustment Data Validation (RADV) audit program for Medicare Advantage plans.Aug. 2025What's New